Evidence map›Paper›PMID 37546906›Full record

ArticlebioRxiv : the preprint server for biology2023

ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.

Vianne R Gao, Rui Yang, Arnav Das, Renhe Luo, Hanzhi Luo, Dylan R McNally, Ioannis Karagiannidis, Martin A Rivas, Zhong-Min Wang, Darko Barisic and 14 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Vianne R GaoComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rui YangComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnav DasUniversity of Washington, Seattle, WA, USA.
Renhe LuoDevelopmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
Hanzhi LuoMolecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dylan R McNallyCaryl and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Ioannis KaragiannidisDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Martin A RivasDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Zhong-Min WangHoward Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Darko BarisicDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Alireza KarbalaygharehComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wilfred WongComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yingqian A ZhanCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christopher R ChinDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
William NobleUniversity of Washington, Seattle, WA, USA.
Jeff A BilmesUniversity of Washington, Seattle, WA, USA.
Effie ApostolouSanford I Weill department of Medicine, Sandra and Edward Meyer Cancer center, Weill Cornell Medicine, New York, NY, USA.
Michael G KharasMolecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wendy BéguelinDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Aaron D VinyDepartments of Medicine, Division of Hematology & Oncology, and of Genetics & Development, Columbia Stem Cell Initiative, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Danwei HuangfuDevelopmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
Alexander Y RudenskyHoward Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ari M MelnickDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Washington · USKettering University · USColumbia University Irving Medical Center · US

Funding

Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune InflammationU01HG012103 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI Christina S Leslie, Alexander Y Rudensky · 2021 to 2026
$7.5M
Uncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2M
Discovery of diabetes-relevant β cell enhancers through 4D enhancer mapping, integrative analysis, and large-scale CRISPRi perturbation screensU01DK128852 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI APOSTOLOU, EFFIE, HUANGFU, DANWEI · 2020 to 2024
$3.5M
Preventing follicular lymphoma progression and transformation through precision therapyR01CA270245 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Wendy Beguelin · 2022 to 2026
$2.2M
Role of Chromatin Remodeling Complex BAF in Immunity and LymphomaK99CA246080 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARISIC, DARKO · 2020 to 2022
$381k
Defining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions -supplementK99DK128602 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, HANZHI · 2021 to 2023
$235k
NCI NIH HHS K99 CA246080NCI NIH HHS R01 CA270245NHGRI NIH HHS U01 HG012103NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R01 DK101989NIDDK NIH HHS U01 DK128852
6 · The paper itself

Abstract

The identification of cell-type-specific 3D chromatin interactions between regulatory elements can help to decipher gene regulation and to interpret the function of disease-associated non-coding variants. However, current chromosome conformation capture (3C) technologies are unable to resolve interactions at this resolution when only small numbers of cells are available as input. We therefore present ChromaFold, a deep learning model that predicts 3D contact maps and regulatory interactions from single-cell ATAC sequencing (scATAC-seq) data alone. ChromaFold uses pseudobulk chromatin accessibility, co-accessibility profiles across metacells, and predicted CTCF motif tracks as input features and employs a lightweight architecture to enable training on standard GPUs. Once trained on paired scATAC-seq and Hi-C data in human cell lines and tissues, ChromaFold can accurately predict both the 3D contact map and peak-level interactions across diverse human and mouse test cell types. In benchmarking against a recent deep learning method that uses bulk ATAC-seq, DNA sequence, and CTCF ChIP-seq to make cell-type-specific predictions, ChromaFold yields superior prediction performance when including CTCF ChIP-seq data as an input and comparable performance without. Finally, fine-tuning ChromaFold on paired scATAC-seq and Hi-C in a complex tissue enables deconvolution of chromatin interactions across cell subpopulations. ChromaFold thus achieves state-of-the-art prediction of 3D contact maps and regulatory interactions using scATAC-seq alone as input data, enabling accurate inference of cell-type-specific interactions in settings where 3C-based assays are infeasible.

Identifiers

PMID37546906
PMCPMC10402156
OpenAlexW4385333069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.